946525-34-4

Basic information

• Product Name: 1-bromo-4-(1-methoxy-β-D-glucopyranosyl)-2-(phenoxymethyl)benzene
• Synonyms: 1-bromo-4-(1-methoxy-β-D-glucopyranosyl)-2-(phenoxymethyl)benzene
• CAS NO: 946525-34-4
• Molecular Weight: 455.302
• Mol File: 946525-34-4.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1-bromo-4-(1-methoxy-β-D-glucopyranosyl)-2-(phenoxymethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-4-(1-methoxy-β-D-glucopyranosyl)-2-(phenoxymethyl)benzene(946525-34-4)
• EPA Substance Registry System: 1-bromo-4-(1-methoxy-β-D-glucopyranosyl)-2-(phenoxymethyl)benzene(946525-34-4)

Safety Data

• Hazardous Substances Data: 946525-34-4(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 956006-88-5 4-bromo-1-iodo-3-phenoxymethyl-benzene 
• 1261570-98-2 2-bromo-5-iodobenzoyl chloride 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 
• 75-75-2 methanesulfonic acid 
• 25252-00-0 2-bromo-5-iodobenzoic acid 

Downstream Products

• 946525-35-5 1-bromo-4-(2,3,4,6-tetra-O-acetyl-1-deoxy-D-glucopyranos-1-yl)-2-(phenoxymethyl)-benzene 
• 1539295-26-5 1-cyano-2-(4-cyclopropylbenzyl)-4-(β-D-glucopyranos-1-yl)benzene L-proline 
• 946525-36-6 2-(phenoxymethyl)-4-(2,3,4,6-tetra-O-acetyl-1-deoxy-D-glucopyranos-1-yl)-benzonitrile 
• 946525-37-7 2-bromomethyl-4-(2,3,4,6-tetra-O-acetyl-1-deoxy-D-glucopyranos-1-yl)-benzonitrile 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE

The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more sele